Cystoscopy Remains Best Method for Surveillance of Patients with Bladder Cancer (3/10/2010)
Researchers from the M. D. Anderson Cancer Center have reported that cystoscopy alone remains the most cost-effective method of detecting recurrent superficial bladder cancer. The details of this study were presented at the 2010 American Society of Clinical Oncology Genitourinary Cancers Symposium March 5-7 in San Francisco.

Combined Modality Therapy Spares Cystectomy in Majority of Patients with Locally Advanced Bladder Cancer (3/9/2010)
Researchers from the Massachusetts General Hospital have reported that 75% of patients with locally advanced bladder cancer can be treated successfully with combined modality therapy that preserves the bladder. The details of this 15-year study were presented at the 2010 American Society of Clinical Oncology Genitourinary Cancers Symposium March 5-7 in San Francisco.

Robotic-assisted Cystectomy More Expensive than Open Surgery for Bladder Cancer (1/22/2010)
Researchers from the University of North Carolina at Chapel Hill have reported that robotic assisted cystectomy is associated with an average cost of $16,248 versus $14,608 for open cystectomy for bladder cancer. The details of this study appeared in the February, 2010 issue of the Journal of Urology.

The Incidence of Smoking-related Bladder Cancer May Be Increasing (11/19/2009)
Researchers from the National Cancer Institute and Dartmouth Medical School have reported that the risk of developing smoking-related bladder cancer has increased in New Hampshire over the risk observed in the 1990s. The details of this study appeared in the November 18, 2009 issue of the Journal of the National Cancer Institute.

Intravesical Taxotere® Maintenance Therapy May Improve Treatment of Superficial Bladder Cancer Refractory to BCG (11/18/2009)
Researchers from Columbia University have reported that induction and maintenance therapy with intravesical Taxotere® (docetaxel) is well tolerated and effective for treatment of patients with non-muscle-invasive bladder cancer who are refractory to Bacilli Calmette-Guerin (BCG) therapy. The details of this study were reported in the October 2009 issue of British Journal of Urology International.